Search
silodosin (Rapaflo)
FDA approved Oct 2008
Indications:
- benign prostatic hypertrophy
- urinary calculus [3]
Contraindications:
- creatinine clearance < 30 mL/min
Dosage: 8 mg QD
Tabs: 4 mg, 8 mg Dosage adjustment in renal impairment:
- 4 mg QD for men with moderate renal impairment
- not recommended for men with severe renal or hepatic impairment
Adverse effects:
- reduced semem during orgasm (most common)
- retrograde ejaculation, more common than with non-selective alpha-blockers
- dizziness, light-headedness, orthostatic hypotension
- diarrhea
- headache
- pharyngitis, nasal congestion
- risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery
Mechanism of action:
- blocks alpha-1 receptors in the prostate, bladder, & urethra, relaxing smooth muscle
Interactions
drug adverse effects of alpha-1 adrenergic receptor antagonists
General
alpha-1 adrenergic receptor antagonist; prostate-selective alpha blocker
References
- FDA News
FDA Approves Rapaflo for the Treatment of Symptoms Due to an
Enlarged Prostate Gland
http://www.fda.gov/bbs/topics/NEWS/2008/NEW01902.html
- Prescriber's Letter 16(5) 2009
Comparison of Alpha1-Blockers
Detail-Document#: 250505
(subscription needed) http://www.prescribersletter.com
- Deprecated Reference